Brain and Spinal Tumors Research Studies

< Back to Young Adult Cancer Research Studies Page

Neurofibromatosis Sarcoma MPNST New Diagnosis

A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

  • Ages: 6 Months to 21 Years  

To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs) [ Time Frame: During the first 28-day cycle of LOXO-292 treatment ] LOXO-RET-18036:  A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric P ...More

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi)

  • Ages: 18 years or older

The primary goal is to evaluate nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo. NIR-DT-301: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Vers ...More